[8-K] Aligos Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.

• Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
• Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
• All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
• Shares outstanding on record date: 5,314,801.

The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.

Positive

• None.

Negative

• Authorized voting common stock increased from 20,000,000 to 100,000,000, creating significant potential dilution.
• Non-voting common stock authorization expanded from 800,000 to 15,800,000, potentially reducing voting power for future investors.
• 2020 Incentive Award Plan enlarged by 1,000,000 shares, equating to ~19% of current shares outstanding, increasing stock-based compensation dilution.

Insights

Equity Analyst

TL;DR – Fivefold share authorization sharply raises dilution overhang.

The jump to 100 million authorized shares versus only 5.3 million outstanding signals future equity issuance is likely. While this enlarges financing flexibility for costly clinical programs, it also places a substantial dilution overhang on current investors. The additional 1 million shares for the 2020 Plan alone equals roughly 19% of present shares, amplifying stock-based compensation expense. Vote tallies (~87% approval) show strong insider/supporter backing, limiting near-term governance pushback. Without accompanying business milestones or financing details, the filing skews negative from a valuation standpoint.

Corporate Governance Specialist

TL;DR – Governance process proper; scope of share hike unusually large.

Procedurally, the board secured prior shareholder consent and disclosed full vote counts, aligning with best-practice governance. However, expanding voting authorization 5× and non-voting 20× is atypical for a micro-cap and could dilute minority influence, especially if non-voting stock is used in future financings. Compensation plan expansion may signal retention needs in a competitive biotech talent market, but also pressures the equity pool every year via the evergreen formula. Overall impact is mixed: enhanced strategic optionality vs. weakened shareholder protections.

false 0001799448 --12-31 0001799448 2025-06-25 2025-06-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2025

Aligos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39617		82-4724808
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

One Corporate Dr., 2nd Floor South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(800) 466-6059

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		ALGS		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 25, 2025, Aligos Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). As further described in Item 5.07 of this Current Report on Form 8-K, at the Annual Meeting, the Company’s stockholders approved an amendment (the “2020 Plan Amendment”) to the Company’s 2020 Incentive Award Plan (the “2020 Plan”). The 2020 Plan Amendment was approved by the Board of Directors (the “Board”) on April 11, 2025 and became effective upon stockholder approval at the Annual Meeting.

The 2020 Plan Amendment amends the 2020 Plan (as amended, the “Amended Plan”) to increase the number of shares reserved and scheduled to be reserved under the 2020 Plan by 1,000,000 shares, such that the number of shares reserved for issuance under the 2020 Plan will equal an aggregate of the sum of (i) 177,072 shares of common stock; (ii) any shares of common stock that were subject to awards outstanding under the 2018 Equity Incentive Plan as of October 14, 2020 that become available for issuance under the 2020 Plan pursuant to Article V of the 2020 Plan; (iii) an annual increase on the first day of each calendar year beginning in 2021 and ending in 2030, equal to the lesser of (A) 5% of the shares of common stock outstanding or, commencing January 1, 2025, issuable upon exercise of outstanding pre-funded warrants with an exercise price per share equal to one penny or less, in each case, on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of common stock as determined by the Board; and (iv) 1,000,000 shares of common stock.

The terms and conditions of the Amended Plan are described in the section entitled “Proposal 3 – Approval of Amendment to our 2020 Incentive Award Plan” included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2025 (the “Proxy Statement”). This description is incorporated by reference into Item 5.02 of this Current Report on Form 8-K.

The above and the incorporated descriptions of the Amended Plan are qualified in their entirety by reference to the 2020 Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 20,000,000 shares to 100,000,000 shares and to increase the number of authorized shares of non-voting common stock from 800,000 shares to 15,800,000 shares. The increase in the number of authorized shares voting common stock and non-voting common stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 25, 2025 and was effective as of such date.

The above description is qualified in its entirety by reference to the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the Company’s stockholders voted on five proposals, each of which is described in more detail in the Proxy Statement. Only stockholders of record as of the close of business on April 28, 2025, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 5,314,801 shares of the Company’s voting common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of three Class II directors to hold office until the 2028 annual meeting of stockholders or until their respective successor is elected. The results of the vote were as follows:

Nominee		Votes For				Votes Withheld				Broker Non-Votes
K. Peter Hirth, Ph.D.			2,161,021				7,106				1,268,587
Heather Preston, M.D.			2,161,429				6,698				1,268,587
Margarita Chavez			2,161,423				6,704				1,268,587

Proposal 2. The ratification of the selection by the audit committee of the Board of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025. The results of the vote were as follows:

Votes For		Votes Against		Abstentions
3,429,953		4,968		1,793

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 3. The approval of an amendment to the 2020 Plan to increase the number of shares reserved and scheduled to be reserved under the 2020 Plan by 1,000,000 shares. The results of the vote were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
1,928,200		238,399		1,528		1,268,587

Proposal 4. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of voting common stock from 20,000,000 shares to 100,000,000 shares. The results of the vote were as follows:

Votes For		Votes Against		Abstentions
2,938,972		392,536		105,206

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Proposal 5. The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of non-voting common stock from 800,000 shares to 15,800,000 shares. The results of the vote were as follows:

Votes For		Votes Against		Abstentions
2,920,916		410,528		105,270

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aligos Therapeutics, Inc.
10.1		Amendment to the Aligos Therapeutics, Inc. 2020 Incentive Award Plan.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				ALIGOS THERAPEUTICS, INC.
Date: June 26, 2025				By:		/s/ Lesley Ann Calhoun
						Lesley Ann Calhoun
						Executive Vice President, Chief Operating Officer and Chief Financial Officer

FAQ

Why did ALGS increase its authorized voting common shares to 100 million?

Shareholders approved a Certificate of Amendment to provide additional capacity for future equity issuances, financings, and corporate purposes.

How many new shares were added to ALGS’s 2020 Incentive Award Plan?

The plan was increased by 1,000,000 shares, effective upon shareholder approval on June 25, 2025.

What percentage of shareholders supported the voting share increase at ALGS?

Approximately 87% of votes cast (2,938,972 for vs. 392,536 against) supported the authorized share increase.

How many ALGS shares were outstanding on the record date for the 2025 Annual Meeting?

There were 5,314,801 voting common shares outstanding as of April 28, 2025.

Did ALGS disclose any financial results in this 8-K filing?

No. The filing focused on governance matters and did not present financial performance or guidance.